Amphista Therapeutics

As 2022 draws to a close, an unusually low number of marquee deals have been made in the biopharma sector. But it has been a hectic year nonetheless, with a high volume of deal-making and the lower va

On the same day the Bristol Myers Squibb Company collaboration was signed, Amphista Therapeutics penned a similar deal with Merck & Co., Inc. for protein degraders. The Merck agreement is worth

With sentiment turning against the biotech sector in the public markets, leading European life science venture capital firm Forbion has put together a new fund that could be worth €600m to tap into so

Targeted protein degradation has become one of the hottest areas of biotech R&D and pharma deal-making in recent times and this week has seen a flurry of mixed news typical of exciting but early-stage